SATB1 and Familial prostate cancer: In vitro experiments showed that combined treatment (ZD55-SATB1 plus DTX) had the highest efficacy to inhibit the viability, invasion and migration of prostate cancer cells while had no significant effect on the viability of normal prostate cells.